G1 Therapeutics Stock Price. Everything You Need To Know About The G1 Therapeutics Stock!
G1 Therapeutics, Inc. is a biopharmaceutical company that specializes in the development of small molecule therapeutics for cancer patients. The company, which is headquartered in Research Triangle Park, North Carolina, employs approximately 170 full-time staff members. G1 Therapeutics went public on May 17th, 2017, marking a significant milestone for the company.
The firm is dedicated to creating and commercializing small molecule therapeutics to improve cancer patients’ quality of life. COSELA (trilaciclib), the company’s lead commercial product, is a revolutionary therapy designed to assist and safeguard hematopoietic stem and progenitor cells (HSPCs) in bone marrow by transiently inhibiting CDK4/6 in patients with extensive-stage small cell lung cancer (ES-SCLC) against chemotherapy-induced myelosuppression.
G1 Therapeutics’ Lerociclib is another promising clinical-stage oral CDK4/6 inhibitor that is being developed for use in combination with other targeted therapies in multiple oncology indications. Furthermore, Rintodestrant, an oral selective estrogen receptor degrader (SERD), is being evaluated as a monotherapy and in combination with CDK4/6 inhibitors, specifically Ibrance (palbociclib), for the treatment of estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2 (HER2)-breast cancer.
It is essential to conduct thorough research and analysis before investing in G1 Therapeutics or any other stock, particularly in the biopharmaceutical sector. Staying current with industry trends is crucial to making well-informed decisions.
G1 Therapeutics Stock Price. Everything You Need To Know About The G1 Therapeutics Stock! performance
- Employees 170
- Company HQ RESEARCH TRIANGLE PARK
- Website https://www.g1therapeutics.com/
- GTHX Asset Type Common Stock
- GTHX Market Capitalization 208.3M
- Earnings Per Share -0.93
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
G1 Therapeutics is an innovative biopharmaceutical company focused on developing novel therapies for the treatment of cancer. They specialize in the discovery and development of small molecule drugs that target specific proteins involved in cancer cell growth. With their promising pipeline and strong track record, G1 Therapeutics presents an exciting investment opportunity for retail investors from Malaysia, Thailand, Indonesia, and Vietnam. But how can investors from these countries take advantage of this opportunity? With Zorion, an investment platform designed to help retail investors make informed decisions, investing in G1 Therapeutics becomes easier than ever. Through Zorion, investors can access investment insights and recommendations, as well as educational resources to enhance their investment knowledge. Start investing in G1 Therapeutics today and be a part of the future of cancer treatment.
